Redeye comments on Initiator Pharma’s announcement of a directed share issue of approximately DKK8.2m to the new investor Klockhuset Investment, with attached warrants that could provide a further DKK8.2m during H1 2027. The issue is priced at a moderate discount and adds a long-term specialist investor to the shareholder base. We view the raise as favourable for the company as it provides much-needed cash and extends the runway into 2028.
LÄS MER
